CD19 and neoplasm: In addition, some B-cell markers sometimes correspond to a poorer prognosis, such as CD19 (which was found to be associated with a poor prognosis in studies of breast and gastric cancers) and CD79a expression on immature myeloid cells, contributing to their tumour-promoting effects [39, 108, 109].